BioSpace News Archive

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) dise

- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalc

- $46M in Financing Secured from leading global life science investors - Frederick Beddingfield Appointed as CEO

Following a recent FDA meeting, the Phase 2b SOOTHE trial in refractory chronic cough patients remains on track to initiate in Q4 2020

MedX Health Corp. will be presenting at this year’s virtual Fall Investor Summit on Tuesday, November 17th at 4:00PM (EST) / 1:00PM (PST),

Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of new tumor-targeting agents and immuno-oncology agents and their combination therapies, today announced that APL-102 has received China Investigational New Drug (IND) approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the initiation of a Phase 1 pharmacokinetic

HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reports its financial results for the third quarter ended September 30, 2020 and provides a corporate update. “The third quarter saw continued advancement and validation of our clinical development programs, with a focus on our oncology pipeline of replicating arenavirus-based

Early access program launched for the next generation of the ARESupa Universal Pathogenome Assay based on targeted next-generation sequencing (NGS) of native specimens

Translate Bio announced that the Company will participate in the following upcoming investor conferences:

Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter, fiscal year 2021 operating results on Tuesday, November 17, 2020 before the open of the U.S. financial markets. P